You’re invited to a symposium on colon health.

**COLORECTAL CANCER SYMPOSIUM 2019: From Early Detection to Survivorship**

An update for the primary care physician and registered nurse

Saturday, April 27, 2019
7:45 a.m. - 12:45 p.m.

Register online at care.honorhealth.com/colorectal-cancer-symposium-2019

This CME event is not supported by any commercial entity or joint partnership.

**Colon Health Symposium**

HonorHealth invites you to a colorectal cancer symposium from 7:45 a.m.-12:45 p.m. Saturday, April 27.

The symposium focuses on critical information you need to know as a primary care provider, including:

- Imaging and genetic testing in early detection.
- Surgical treatment and options.
- Medical oncology standards of care.
- Colorectal clinical research.

Register online at care.honorhealth.com/colorectal-cancer-symposium-2019

This conference has been approved by the American Society of Radiologic Technologists (ASRT) for 6 Category A CE’s. Attendees must be present for all lectures to receive credit.

**Acknowledgment:** This CME event is not supported by any commercial entity or joint partnership.

**Disclosure:** Dr. Sharma discloses that he has received grant/research support from Toray Industries, Celgene, Hengrui, OncoMed, Plexxikon, Tesaro, AADI, Syndax, and Merck; is a stock/shareholder of Beta Cat Pharmaceuticals, Celgene Pharmaceuticals, ConverGene, Stingray Therapeutics, and Proteus Therapeutics; and that he received honoraria from Loxo Oncology, Exelixis, Hengrui Pharmaceuticals, Tesaro Therapeutics, and Dracen Pharmaceuticals. Sarah Highlander, PhD, discloses that she has received grant/research support from University of Southern California. All other speakers and members of the planning committee have no relevant financial relationships with a commercial interest to disclose.

**Accreditation Statement:** HonorHealth is accredited by the Arizona Medical Association to provide continuing medical education for physicians.

**Credit Statement:** HonorHealth designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PRESENTATION TOPICS

COLON CANCER: From Early Detection to Survivorship

Welcome and opening remarks
Sunil Sharma, MD, FACP, MBA
Chief, Translational Oncology Research & Drug Discovery HonorHealth Research Institute
Conference Director

Paul Sieckmann, MD, Primary Care Physician
Chief Medical Officer, HonorHealth Medical Group
Colorectal cancer (CRC) care from the Primary Care perspective.

OBJECTIVES:
- Discuss the role of the Primary Care Provider in CRC detection.
- Describe patient-risk assessment for CRC from the Primary Care perspective.

Deepa Shah, MD, FACP, Gastroenterologist
Role of the Gastroenterologist in colorectal cancer detection and treatment

OBJECTIVES:
- Review evidence-based CRC screening guidelines including opportunities and challenges of screening at 45 vs 50.
- Discuss the goals of routine screening by colonoscopy and recent advancements in CRC screening. Review HonorHealth CRC Screening guidelines.

Phillip Moeser, MD, Radiologist
Imaging of Colorectal Cancer

OBJECTIVES:
- Explain the role of imaging in the detection, clinical staging and treatment assessment of CRC.
- Describe the importance of MRI in rectal tumor imaging.

Neeraj Singh, MD, Colorectal Surgeon
Surgical approaches to CRC treatment

OBJECTIVES:
- Review current surgical treatments for CRC.
- Outline the role of minimally invasive surgery.
- Identify surgical treatment options for patients with limited metastatic disease.
- Discuss enhanced patient recovery after colon surgery.

Cory R. Fraser, MD, Pathologist
Pathologic diagnosing and molecular testing of CRC

OBJECTIVES:
- Summarize the pathologic evaluation and staging of CRC.
- Review the implications of molecular testing in CRC as it relates to targeted therapy.

Michael Gordon, MD, Medical Oncologist
Treatment options for CRC patients

OBJECTIVES:
- Discuss current CRC therapies based on evidence-based national guidelines and prognostic indicators.
- Describe new approaches to CRC treatment.

Sunil Sharma, MD, FACP, MBA, Research, Medical Oncologist, Chief, Translational Oncology Research & Drug Discovery, HonorHealth Research Institute
New treatments for patients with CRC

OBJECTIVES:
- Discuss the opportunities for clinical trials in the treatment of CRC.
- Summarize how CRC patients should be introduced to clinical trials.
- Discuss importance of early detection and recognizing the high risk patient.

Terri Taylor, RD, CSO
Diet and nutrition as it relates to CRC

OBJECTIVES:
- Review diet recommendations to reduce CRC risk.
- Discuss nutrition recommendations during and after treatment for CRC.

Keynote Speaker: Sarah Highlander, PhD, Director, TGen Clinical Microbiome Services Center

The human microbiome and its emerging role in health and disease: focus on colon cancer

OBJECTIVES:
- Identify the importance of the microbiome as it relates to health, disease and colon cancer.

Dana Brown, MSC, Certified Genetic Counselor
Familial susceptibility of CRC patients and their family.

OBJECTIVES:
- Summarize the role of the genetic counselor in the evaluation of individuals at risk for CRC.
- Outline the use of genetic testing in patients with CRC.

Dawn Bassett, MSN, Ed, RN, OCN, Oncology Nurse Navigator
Role of the Nurse Navigator in CRC care

OBJECTIVES:
- Explain the role of the nurse navigator and the benefits to patients/caregivers.
- Express how navigation can improve patient outcomes.

ACKNOWLEDGMENT

This CME event is not supported by any commercial entity or joint partnership.

Disclosure: Dr. Sharma discloses that he has received grant/research support from Takeda, Eisai, Gilead, Hengrui, OncoMed, Plexxikon, Tesaro, AstraZeneca, and Merck; is a stock/shareholder of Beta Cell Pharmaceuticals, Salient Pharmaceuticals, Convirata, Staging Therapeutics; and Proteus Therapeutics; and that he received honoraria from Leox Oncology, Eislei, Hengrui Therapeutics, Takeda Therapeutics, and Dafiex Pharmaceuticals.

Sarah Highlander, PhD, discloses that she has received grant/research support from University of Southern California. All other speakers and members of the planning committee have no relevant financial relationships with a commercial interest to disclose.

Accreditation Statement: HonorHealth is accredited by the Arizona Medical Association to provide continuing medical education for physicians.

Virginia G. Piper Cancer Care Network

Credit Statement: HonorHealth designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit commensurate with the extent of their participation in the activity.